TANDEM DIABETES CARE INC
TNDMTandem Diabetes Care, Inc. is an American medical-device company that develops and markets insulin pumps, automated insulin delivery systems and diabetes-management software. Headquartered in San Diego, California, its principal pump platforms are the t:slim X2 and Tandem Mobi, both of which use the company's Control-IQ+ software with compatible continuous glucose monitors (CGMs).
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TNDM Earnings Report
EPS Est: $-0.34 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How TNDM's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is TANDEM DIABETES CARE INC's next FDA catalyst?→
TANDEM DIABETES CARE INC's (TNDM) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TNDM biotech catalysts?→
Add TNDM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TANDEM DIABETES CARE INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.